You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
基石藥業(02616.HK)治療胃癌藥物臨牀研究達到主要終點
阿思達克 11-11 08:55
基石藥業-B(02616.HK)公佈,舒格利單抗注射液聯合化療一線治療無法手術切除的局部晚期或轉移性胃/胃食管結合部腺癌的GEMSTONE-303研究達到主要終點之一:無進展生存期(PFS)。 舒格利單抗聯合化療作爲局部晚期胃/胃食管結合部腺癌的一線治療可顯着改善PFS,將疾病進展或死亡風險降低34%;總生存期(OS)呈現明顯獲益的趨勢。在所有預設亞組中均觀察到臨牀獲益。舒格利單抗成爲全球首個在胃/胃食管結合部腺癌III期研究中取得積極結果的PD-L1單抗,並已在四項註冊性臨牀研究中取得積極結果。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account